Diabetic nephropathy and proximal tubule ROS: Challenging our glomerulocentricity  by Bagby, S.-P.
Kidney International (2007) 71       1199
commentar y
therapy). In this study, the actual incidence 
of post-transplant lymphoproliferative dis-
ease was similar in patients treated with IL-
2 receptor antibodies versus patients who 
received no induction therapy but was 
signifi cantly lower in these groups than in 
patients who received depleting antibodies 
as induction treatment.
Whether mycophenolate mofetil 
(MMF) may reduce the risk of cancer is 
currently unclear. Although the analysis 
by Wimmer et al.2 suggests that MMF 
may even enhance the risk of cancer, 
when combined with calcineurin inhibi-
tors, this conclusion could be biased by 
the retrospective design of their study and 
the preferential assignment of MMF to 
older recipients. Robson et al.10 prospec-
tively examined the risk of lymphoma and 
other malignancies in 6751 de novo renal-
transplant recipients treated with MMF 
and observed a similar risk at 3 years in 
comparison with an equal number of 
matched controls receiving non-MMF-
based immunosuppression.
Obviously, malignancy is still a challeng-
ing complication of long-term immuno-
suppression. Immunosuppressive drugs, 
such as mTOR inhibitors and IL-2 recep-
tor antibodies, probably reduce the risk for 
all or some specifi c malignancies and are 
currently tested in clinical trials designed 
to reduce the incidence of some specifi c 
cancers in kidney transplant recipients.
Achieving tolerance, the Holy Grail for 
transplant physicians, would undoubtedly 
obviate the need for lifelong immunosup-
pression and its associated complications. 
Pilot clinical trials are currently running to 
explore the biology of tolerance in humans 
and will hopefully shed more light on the 
feasibility of this goal in the future.
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Diabetic nephropathy and 
proximal tubule ROS: Challenging 
our glomerulocentricity
SP Bagby1
Diabetic nephropathy is currently viewed as a predominantly 
glomerular process with glomerular injury driving secondary tubular 
loss. Brezniceanu and colleagues apply transgenic methods to support 
a prominent role for reactive oxygen species as mediators and for the 
proximal tubule as a major site of early disease activity in diabetes. 
Results support evidence for early tubular apoptosis and atrophy in 
human diabetic nephropathy.
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Diabetic nephropathy has long been 
considered virtually synonymous with 
glomerulosclerosis, the latter viewed as 
the cardinal manifestation and primary 
lesion of this functionally devastating 
disease. Recent gentle challenges to our 
collective dogmatism on this topic have 
emerged, but the paper by Brezniceanu 
and colleagues1 (this issue) takes a giant 
step toward shift ing the glomerulo-tubu-
lar balance in the fi eld. Th ese authors have 
made elegant use of transgenic technol-
ogy to achieve selective overexpression of 
catalase in the renal proximal tubular epi-
thelial cell (RPTC). Catalase, an enzyme 
that breaks down H2O2 to inactive com-
ponents, is used as a tool to reduce gen-
eration of reactive oxygen species (ROS) 
and thereby probe their function. Using 
the RPTC-specifi c, androgen-regulated 
KAP promoter to drive transgenic cata-
lase expression, Brezniceanu and col-
leagues1 found that adult males exhibited 
spontaneous overexpression of catalase 
protein and activity in RPTCs, without 
the addition of exogenous androgen. Th e 
investigators accordingly used the wild-
type and transgenic adult male mice to 
examine the role of ROS in early strepto-
zotocin (STZ)-induced diabetic nephrop-
athy, specifi cally asking whether limiting 
ROS generation attenuates selected dia-
betes-induced abnormalities in the prox-
imal tubule: increased angiotensinogen 
(Agt), plasminogen activator inhibitor-1, 
apoptosis, and histologic injury following 
2 weeks of diabetes.
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Th e emphasis by Brezniceanu and col-
leagues1 on the proximal tubule rather 
than the glomerulus is the fi rst of several 
surprises. A handful of recent studies have 
in fact documented prominent tubular 
atrophy in both human and experimen-
tal diabetes. In eight type 1 diabetics with 
stage I–II chronic kidney disease, Naja-
fi an et al.2 found by stereologic methods 
that atubular glomeruli and glomeruli 
attached to atrophic tubules made up 68% 
of all glomeruli, while fractional volumes 
of atrophic tubules were increased and 
those of normal tubules were reduced. 
Also in human diabetic kidneys, Kumar 
et al.3 demonstrated increased apopto-
sis localized to tubular and interstitial 
cells but, interestingly, not present in the 
glomerulus; a similar pattern was found 
in STZ-induced diabetic nephropathy 
in rats.4 Collectively, these reports point 
to a previously unrecognized atrophic 
process in the diabetic tubule and sug-
gest that specifi cally tubular apoptosis 
may contribute.
The choice by Brezniceanu and col-
leagues1 to monitor expression of Agt in 
the proximal tubule refl ects the recent 
recognition of an independently regu-
lated intrarenal renin–angiotensin sys-
tem (RAS) localized to the RPTC. Th e 
classic circulating RAS is based on renin 
secretion by the juxtaglomerular cells of 
the afferent arteriole; circulating renal 
renin in turn requires circulating Agt 
from liver and angiotensin-convert-
ing enzyme at the endothelial surface to 
eff ect angiotensin II (Ang II) production. 
Th e intrarenal RAS, on the other hand, 
appears to be self-contained, as all com-
ponents required for Ang II generation 
can be synthesized within the RPTC.5 In 
contrast to the negative feedback exerted 
by Ang II on juxtaglomerular-cell renin 
secretion, the intrarenal RAS operates via 
a positive-feedback response to Ang II.6 
In addition, Ang II in the tubular lumen 
is also actively taken up into RPTCs, in 
part by angiotensin receptor type 1 bind-
ing/internalization.7 Once inside, Ang II 
stimulates increased RPTC expression 
of both Agt and renin, and thus a feed-
forward eff ect promoting more Ang II 
formation. By these processes, chronic exog-
enous Ang II infusion leads to increased 
Ang II in kidney cortex and specifi cally 
in the renal interstitial fl uid.8 Renal inter-
stitial Ang II levels have been found to be 
many-fold higher than plasma levels and 
to be regulated independently of plasma 
Ang II.9,10 Recent studies also show that 
transgenic overexpression of Agt confi ned 
to the RPTC is alone suffi  cient to induce 
systemic hypertension,11,12 lending sup-
port in principle to the concept that intra-
renal RAS activation dominates extrarenal 
regulators of blood pressure. Of particu-
lar relevance to the article by Brezniceanu 
and colleagues,1 these Agt overexpression 
studies demonstrate that Agt excess alone 
appears capable of initiating intrarenal 
RAS activation.
The intrarenal RAS has generated 
intense interest in the setting of diabe-
tes, where it was first appreciated that 
an activated intrarenal RAS can coexist 
with a suppressed circulating RAS. In 
experimental diabetes, investigators have 
subsequently confi rmed an increase in 
intrarenal Ang II levels,13 together with 
increased renin14 and increased Agt15 in 
the early stages of diabetic nephropathy. 
Th ere is, additionally, solid evidence that 
both high glucose15 and elevated Ang II16 
— considered the two most potent patho-
physiologic agonists in diabetic nephropa-
thy — induce increased ROS generation 
in proximal tubular and mesangial cells 
in vitro, and that ROS excess may in turn 
mediate tissue injury and apoptosis. How-
ever, we have not had evidence that can 
assign priority or establish a molecular 
sequence for how these signaling elements 
interact in vivo.
Brezniceanu and colleagues1 designed 
the transgenic model noted above to test 
in vivo the importance of ROS in medi-
ating early diabetic nephropathy. The 
authors first clearly demonstrate that 
catalase overexpression is confi ned to the 
proximal tubule and is functional in situ: 
isolated renal proximal tubules from the 
male transgenic mice exhibited virtually 
no increase in ROS and no increase in Agt 
mRNA or protein expression in response 
to either Ang II or high glucose, in con-
trast to the vigorous responses in wild-type 
renal proximal tubules. Turning next to the 
STZ-diabetic state, Brezniceanu and col-
leagues1 show similar outcomes in isolated 
renal proximal tubules from STZ-diabetic 
transgenic versus diabetic wild-type mice: 
catalase overexpression prevented the dia-
betes-induced increases in Agt expression, 
in the proinfl ammatory ROS-dependent 
plasminogen activator inhibitor-1, in 
apoptosis-inducing enzyme caspase-3 
and p53, and in tubular-cell apoptosis. 
Finally, by standard renal histologic and 
immunochemical approaches, the authors 
confi rmed in vivo by TdT-mediated dUTP 
nick end labeling that catalase overexpres-
sion prevented increases in RPTC Agt pro-
tein, apoptotic enzymes, and apoptosis in 
the STZ-diabetic transgenic kidneys. Th e 
molecular targets were chosen for their 
known sensitivity to ROS, underscor-
ing the conclusion that constrained ROS 
generation in fact mediated the outcomes. 
Th us, we can reasonably predict that the 
processes represented by these molecules 
— specifi cally, intrarenal RAS activation, 
infl ammation, and apoptosis — are down-
stream consequences of increased oxida-
tive stress in early diabetic nephropathy.
Th e eff ects of transgenic catalase over-
expression in diabetic RPTCs are equally 
interesting for what was not blocked. 
Proteinuria in diabetic transgenic mice 
persisted at levels comparable to those in 
diabetic wild-type mice. Th is is perhaps a 
refl ection of the preserved hypergly cemia 
with its expected effects at glomerular 
sites. It is nonetheless a reminder that 
excess protein continued to bombard the 
catalase-overexpressing RPTCs in the 
diabetic transgenic mice. Hyperglycemia 
enhances tubular uptake of albumin17 and 
induces RPTC surface expression of CD36, 
mediating increased uptake of advanced 
glycosylation endproducts- modified 
albumin.18 It is interesting to speculate 
that the favorable results of limiting ROS 
in RPTCs might in part refl ect prevention 
of the inflammatory and proapoptotic 
eff ects of excess RPTC albumin uptake.19 
If true, this would predict an additional 
contribution of proteinuria-related injury 
in the early phase of diabetic nephropathy 
and raises the question of ROS-depend-
ence of protein-induced tubulointersti-
tial injury. Figure 1 proposes one way of 
integrating the fi ndings of Brezniceanu 
and colleagues1 and others in the fi eld in 
a molecular scheme; major weight is given 
to intrarenal RAS activation and to the 
feed-forward, autoamplifi cation features 
of this system in the RPTC.
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Another intriguing observation by 
Brezniceanu and colleagues1 is the 
apparent failure of catalase overexpres-
sion to block the RPTC hypertrophy in 
diabetic transgenic mice over the 2 weeks 
of STZ-diabetes. Th is also comes as a sur-
prise. Ang II has been reported to induce 
RPTC hypertrophy via ROS-dependent 
pathways.20 Additionally, in prior work by 
Brezniceanu and colleagues in RPTC cell 
culture, hyperglycemia-induced hyper-
trophy was prevented by Ang II recep-
tor blockade,21 suggesting that diabetic 
hypertrophy is Ang II dependent. On the 
basis of these observations, catalase over-
expression would be expected to reduce 
diabetes-associated RPTC hypertrophy. 
The unexpected persistence of RPTC 
hypertrophy perhaps refl ects the greater 
complexity of the in vivo state, which can-
not be fully modeled in the cell-culture 
setting. One is left  to conclude that mech-
anisms of hyperglycemia-induced hyper-
trophy remain far from clear. Yet diabetic 
tubular hypertrophy may well have excep-
tionally important consequences. Recent 
studies by Th omson and colleagues have 
led to an equally tubulocentric proposal: 
that diabetic tubular hypertrophy is the 
primary event in diabetic nephropathy 
and in fact causes glomerular hyperfi l-
tration.22 These investigators propose 
that proximal hypertrophy, via increased 
proximal sodium reabsorption and 
reduced sodium delivery to the macula 
densa, triggers a tubuloglomerular feed-
back response that initiates and sustains 
diabetic hyperfi ltration.22 Th e fi ndings 
of Brezniceanu and colleagues1 appear 
to exclude a role for ROS in mediating 
diabetic RPTC hypertrophy. Studies by 
Th omson and colleagues provide evidence 
that ornithine decarboxylase is essential 
to hyperglycemia-induced RPTC hyper-
trophy.23 Taken together, these fi ndings 
suggest it is likely that neither Ang II 
nor ROS are etiologic, whereas ornithine 
decarboxylase remains in the running as 
a mediator of diabetic tubular hypertro-
phy. It will be important to learn in the 
present model whether persistence of 
diabetic hypertrophy over a longer period 
leads to adverse consequences despite the 
catalase-induced protection from excess 
tubular ROS generation.
Th ere are, as always, caveats to pon-
der. First, the diagnosis of hypertrophy is 
based primarily on kidney weight–body 
weight ratio; Brezniceanu and colleagues1 
did not quantitate RPTC hypertrophy at 
a cellular level by either cell size or pro-
tein–DNA ratio. It thus remains possible 
that the apparent renal enlargement may 
refl ect edema in diabetic transgenic mice, 
a histopathologic feature in fact noted 
by the investigators. If so, resolution of 
hypertrophy might be masked. Second, 
endogenous androgens are important, not 
only postpubertally, but also during fetal 
development (for example, in sex diff er-
entiation); catalase overexpression in fetal 
male RPTCs during development could 
induce programming events that perma-
nently change proximal tubular function 
and confound results in unexpected ways. 
Th us, as usual, diff ering approaches to 
independently confi rm these fi ndings will 
be important. Because these observations 
cover a very early phase of disease, exami-
nation of ROS roles at later stages will also 
be crucial in developing rational thera-
peutic interventions.
Nonetheless, these remarkable fi nd-
ings provide compelling support for 
the in vivo participation of ROS in the 
early phase of diabetic nephropathy and 
for the proximal tubule as a key site of 
early ROS-induced disease activity. Th at 
tubular processes leading to apoptosis 
and atrophy in the proximal tubule may 
drive loss of renal function independently 
of glomerular disease activity would be, 
Figure 1 | A proposal for integrating pathways of diabetic injury in the renal proximal tubular 
epithelial cell (RPTC). On the basis of the work of Brezniceanu and colleagues,1 the early phase 
of the diabetic state leads to increased generation of reactive oxygen species (ROS) in the RPTC. 
Limitation of ROS generation by transgenic overexpression of catalase selectively in the RPTC 
prevented molecular and cellular outcomes associated with (1) intrarenal renin–angiotensin 
system (RAS) generation (increased angiotensinogen mRNA/protein); (2) inflammation 
(plasminogen activator inhibitor-1 (PAI-1) expression); and (3) apoptosis (apoptosis-inducing 
enzymes and apoptosis rate). The cartoon suggests one way of integrating these findings: a 
primary pathway of ROS activation due to high glucose, followed by a secondary, amplifying 
pathway involving intrarenal RAS activation through upregulation of angiotensinogen (Agt). The 
latter could potentially explain, via autoamplifying Ang II generation, both the PAI-1 increase and 
the apoptosis, although independent mechanisms of ROS-induced inflammation and apoptosis 
no doubt participate. This scheme can also explain the effectiveness of RAS blockade in preventing 
renal disease progression in diabetes. ACE, angiotensin-converting enzyme; Ang, angiotensin; 
AT1R, angiotensin receptor type 1; TGFβ, transforming growth factor-β.
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if confi rmed, a paradigm shift  in our cur-
rently glomerulocentric view of diabetic 
nephropathy.
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